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Abstract 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive memory defeat and 
impairment in behaviour, language, and visuospatial skills. Current approved drugs for the treatment of Alzheimer disease 
(AD) include cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and the NMDA receptor antagonist 
memantine. These drugs can provide a symptomatic relief but they poorly affect the progression of the disease. There are 
several risk factors for the development of Alzheimer’s disease which include factors like age, genetic factor family history, 
Down’s syndrome, head injury and cardiovascular diseases. Cardio vascular risk factors may include blood pressure, 
cholesterol, diabetes, obesity and smoking. People may experience cognitive mental illness, difficulty in understanding and 
thinking, forgetting things easily, making things complicated, mental confusion, difficulty in concentrating, inability to 
create old memories, inability to do simple things, or inability to recognize common things. The main objective of this 
review is discussion on various analytical methods used, different solvents used as mobile phase and their retention time. 
This review includes method development and validation of cholinesterase inhibitors like Donepezil, Galantamine, 
Rivastigmine and Tacrine combination of drugs which include cholinesterase inhibitors like Donepezil and NMDA receptor 
antagonist Memantine. The review is a collection of data including various analytical methods used, the different columns 
used, mobile phase used, flow rate, different detectors and detection wavelength and retention time. This review includes 
discussion on method development and validation of Alzheimer’s drugs and newly developed compounds which have 
lesser side effects and are proving more efficient for treatment of Alzheimer’s disease. 
Keywords: Alzheimers Disease, Cholinesterase inhibitors, Dementia, Method Development, Validation.. 
 
1. Introduction 
Alzheimer's disease (AD) is also referred to 
as Alzheimer's, which is a chronic neurodegenerative 
disease that usually starts slowly and then worsens over 
when the disease prolongs. About 60% to 70% cases are 
seen, it is also known as senile dementia.  This disease 
mostly affects the age group of more than 60-65 years of 
age, this disease may be genetically proven, by a family 
history, people with Down’s syndrome are more proven to 
this disease, also cardiovascular diseases can be a major 
cause to this disease like smoking and drinking, high blood 
pressure, diabetic patients, high cholesterol and obesity can 
lead to AD and people with severe head injuries have a 
higher risk to AD, since it leads to dementia and cognition. 
Alzheimer's disease is a progressive disease that destroys 
memory and other important mental functions. 
                 It is a neurological disorder in which the brain 
cells die and causes memory loss and cognitive decline. It is 
a neurodegenerative type of dementia, where the disease 
starts mild and gets progressively worsens as the disease 
prolongs. This disease can be for life long.  
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                  The most common symptom seen in AD is 
difficulty in remembering recent events which is called as 
short-term memory loss. As the disease prolongs, 
symptoms can include problems with speaking and 
language, , mood swings, loss of motivation, not 
managing self care, behavioural changes and issues and 
easily getting lost. Although the disease progression can 
vary, the average life span may decrease from three to nine 
years following diagnosis.  
                  The cause of Alzheimer's disease is poorly 
understood. About 70% of the cause is believed to 
be genetically involved with many genes usually. Other risk 
factors may include a history of head injuries, depression or 
hypertension, hypercholesterolemia, obesity etc. The 
diagnosis is based on the history of the illness and cognitive 
testing with medical and blood tests to rule out other 
possible issues. Initial symptoms are often mistaken for 
normal ageing. Examination of brain cells is needed for a 
definite diagnosis. Mental and physical exercise, and 
avoiding smoking, hypertension, diabetes and obesity may 
decrease the risk of AD. 
Chronic AD can last for years or be lifelong. Brain 
cell connections and the cells themselves degenerate and 
die, eventually destroying memory and other important 
mental functions. Memory loss and confusion are the main 
symptoms. No cure exists, but medication and management 
strategies may temporarily improve symptoms. The method 
development and validation of cholinesterase inhibitors like 
Donepezil, Galantamine, Rivastigmine and Tacrine. 
Combination drugs which include cholinesterase inhibitors 
like Donepezil and NMDA receptor antagonist Memantine 
are discussed in this review. The various analytical methods 
used, the different columns used, mobile phase used, flow 
rate, different detectors and detection wavelength and 
retention time are discussed in this review. 
1.1 The highest risk factors which combat AD include 
1) Age, 2) Family history, 3) Down's syndrome, 4) Severe 
Head injuries, 5) Cardiovascular disease 
Figure 1: Representing the risk factors for AD
 
 
1.2 The five major factors in CVD include:  
1) Smoking,  
2) Obesity,  
3) Diabetes,  
4) Hypertension and High Cholesterol 
 
Figure 2: Represents the risk factors for AD through 
Cardio Vascular Diseases 
 
 
3. Causes of Alzheimer's disease 
The total size of the brain shrinks the tissue has 
very few nerve cells and connections. Nerve cells (neurons) 
in the brain shrink. In Alzheimer's, disease there are 
microscopic 'plaques' and 'tangles' between and within the 
brain cells. Plaques are found between the dying cells in the 
brain from the build-up of a protein called beta-amyloidal. 
The tangles are within the brain neurons from a 
degeneration of another protein, called tau.  
3.1 Various Stages of Alzheimer's disease 
Alzheimer's can be classified into three basic 
stages: Preclinical, Mild cognitive impairment, Dementia. 
 
4. Drug Therapy 
There are four drugs in a class called 
cholinesterase inhibitor Include:   
Donepezil (Aricept),  
Galantamine (Reminyl),  
Rivastigmine (Exelon),  
Tacrine (Cognex),  
Memantine (Namenda), an NMDA receptor 
antagonist, may also be used, alone or in combination with 
a cholinesterase inhibitor. 
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Figure 3: Alzheimer’s disease drug scale 
 
 
Donepezil 
 
A Reverse Phase High Performance Liquid 
Chromatographic (RPHPLC) method was developed for the 
determination of Donepezil HCl tablets, C18 column 
250mm x 4.6mm(l x d) in reverse phase isocratic mode of 
separation with mobile phase methanol : phosphate buffer : 
Triethylamine (60:40:0.5)% v/v were used. The flow rate 
was 1ml/min. [1] 
A RP‐HPLC method has been developed for the 
determination of donepezil hydrochloride in bulk and 
tablets. Separation was achieved with a keystone phenyl RP 
250 × 4.6 mm i.d., 5 μM particle size analytical column 
using mixture of methanol, 0.02M phosphate Buffer (pH 
7.5 ± 0.1) and triethylamine in the ratio 60: 40: 0.5 v/v as 
the mobile phase by Reverse phase isocratic mode. The 
instrumental settings are at a flow rate of 1mL/min, column 
temperature at 40°C and UV detection at 268 nm. The 
retention time was found to be 7.05 min. [2] 
A  Reverse  Phase  High  Performance  Liquid  
Chromatographic (RP-HPLC)  method  was developed  for  
the  determination  of  Donepezil  HCl  tablets,  Xterra  RP  
C 18,  250  x  4.6  mm, 5 in  reverse  phase isocratic  mode  
of  separation  with  mobile  phase  Potassium dihydrogen  
orthophosphate  Buffer  and  Acetonitrile  (80:20)% v/v was 
used. The flow rate was 1ml/min. Detection was done at 
230 nm. [3] 
A new RP-HPLC method was developed and 
validated. Chromatography was carried out using a C18 
(4.6 X 250 mm 3.5μm). A mobile phase consisting of 
Methanol: buffer (60:40%v/v) was pumped at an isocratic 
flow rate of 1ml/min. [4] 
Simple and accurate methods to determine 
donepezil, in tablet dosage form, were developed and 
validated using liquid chromatography (LC). The LC 
separation was achieved on a Inertsil C8-3, 25 cm x 4.6-
mm, 5 μ in the isocratic mode using buffer: methanol: 
triethylamine (550:450:5) v/v, adjusted to pH 2.50±0.05 
with orthophosphoric acid, as the mobile phase at a flow 
rate of 1.0 mL/min. The methods were performed at 271 
nm. The method was validated by determining its 
sensitivity, accuracy and precision. [5] 
RP-HPLC method was developed and validated by 
assessing linearity, accuracy, selectivity, limit of 
quantitation, and precision for the determination of 
Donepezil hydrochloride. Donepezil was identified and 
quantitated on a C18 reversed phase column (3.9×150mm, 
5.0μm), using a mobile phase composed of acetate buffer-
Acetonitrile (50:50v/v) delivered at a flow rate of 
1.0mL/min, and with UV detection (lexcitation = 
230nm).[6] 
Galantamine 
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An accurate and precise RP-HPLC method for 
determination of Galantamine Hydrobromide has been 
developed. Analysis was carried out on Shimadzu HPLC 
system with Phenomenex C18 column (250 x 4.6 mm i.d, 
5μm particle size) using 1 mM ammonium formate: 
acetonitrile (30:70) in Isocratic mode as mobile phase with 
flow rate of 0.4 ml.min-1. The detection was carried out 
using UV detector set at 289 nm. [7] 
The reverse phase high performance liquid 
chromatographic RP-HPLC method has been developed to 
quantify galantamine HBr in raw material and capsule 
formulations using C18 analytical reverse phase column. 
Mobile phase consisted of solution A and solution B 
(75:25v/v) pumped at a flow rate of 1ml/min at 250c 
column temperature. Run time was about 8min with 
symmetrical peaks. Galantamine HBr was detected by PDA 
detector at 230 nm with no interference of excipients. [8] 
 A rapid, accurate and precise RP-HPLC method 
was developed for the determination of Galantamine 
hydrobromide in pure and tablet dosage forms. Separation 
of the drug was achieved on a reverse phase Inertsil ODS 
(100 x 4.6 mm, 5). The method showed a linear response 
for concentration in the range of 30-180 μg/mL using 
phosphate buffer pH 6.3: acetonitrile as the mobile phase in 
the ratio of 60:40, v/v with detection at 285 nm with a flow 
rate of 1 mL/min and retention time was 4.1 min. [9] 
4.1 Memantine HCl and Donepezil HCl 
To develop and validate stability indicating 
method for the analysis of Memantine HCl and Donepezil 
HCl. The chromatographic separation was performed on 
Hypersil BDS (4.6 x 150 mm, 5μ) using Sodium 
dihydrogen ortho phosphate: Acetonitrile (30:70v/v) at a 
flow rate of 1 ml/min and detection of both the eluents was 
carried out by UV Detector. The Retention time of 
Memantine HCl and Donepezil HCl were found to be 2.833 
min. and 4.777 min respectively. [10] 
An accurate RP-HPLC method has been developed 
and validated for the simultaneous estimation of Memantine 
HCl and Donepezil HCl in bulk and pharmaceutical dosage 
form. Chromatographic separation was achieved on Amino, 
Column 250 X 4.8 Mm (5 µm) having mobile phase HPLC 
Grade Water (100%) at a flow rate of 1 mL/min and 
detection of both the eluents carried out by Waters 
Refractive Index Detector (RI Detectors). The retention 
time of MEM and DONE was found to be 3.561 min. and 
4.212 min respectively. [11] 
Memantine 
 
A stability indicating RP-HPLC method has been 
developed and validated by using (2-Napthoxy) Acetyl 
chloride as derivatization agent and Amantadine as an 
internal standard. The separation was achieved by Inertsil 
ODS-3V, 250 x 4.6, 5μm column using mobile phase 
consisting of 0.02 M ammonium acetate buffer and 
methanol in the ratio (12:88) at a flow rate of 1.5 mL/min 
and UV detection at 226 nm. The Method was developed in 
isocratic mode. The retention time for Memantine and 
Amantadine was around 8.62 and 6.23. [12] 
Rivastigmine 
 
An isocratic RP-HPLC Method for analysis of 
Rivastigmine in pharmaceutical dosage forms has been 
developed and validated. Best separation was achieved on a 
Thermo Hypersil C4 column (25 cm X 4.6 mm, 5 μm) 
using a mobile phase of 0.01 M ammonium acetate buffer 
adjusted to pH 4.0 with orthophosphoric acid and 
Acetonitrile (60:40, v/v) at a flow rate of 1.0 mL min-1. UV 
detection was performed at 220 nm. Atrovastatin was used 
as an internal standard. The retention time of Rivastigmine 
and Atrovastatin was 4.75 and 8.83 min, respectively. [13] 
A RP-HPLC method was developed and validated 
for the analysis of rivastigmine bulk dosages form. The 
separation was conducted by using C-18 RP-HPLC column 
which was maintained at ambient temperature. The mobile 
phase consist Potassium dihydrogen phosphate buffer and 
acetonitrile (70/30 v/v) was delivered at a rate of 1ml/min. 
The analysis was detected by using UV detector at the 
wavelength 217nm. The retention time for rivastigmine was 
found to be 3.66±25min. [14]  
A RP-HPLC method was developed and validated 
for the analysis of rivastigmine hydrogen tartrate in 
transdermal drug delivery system. Rivastigmine tartrate is 
soluble in water so it was used as solvent. The separation 
was conducted by using C-18 RP-HPLC column which was 
maintained at ambient temperature. The mobile phase 
consist 0.01M ammonium acetate buffer and acetonitrile 
(70:30 v/v) was delivered at a rate of 1ml/min. The analysis 
was detected by using UV detector at the wavelength 
219nm. The method is validated for its accuracy precision, 
ruggedness, linearity and range. The retention time for 
rivastigmine was found to be 4.40min. [15] 
Tacrine 
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A simple RPHPLC method has been developed for 
determination of Tacrine hydrochloride in bulk and 
nanoemulsion gel using C18 column; 250 mm length, 4.6 
mm internal diameter, 0.5μ particle size with UV visible 
detector (detection wavelength 243nm).Chromatographic 
separation was performed in an isocratic mode with mobile 
phase consisting of 0.05M triethylamine: acetonitrile (80: 
20,); pH 3 using methanol as a diluent at a flow rate of 1.5 
ml/minutes. Retention time was found to be 5.8 minutes. 
[16]  
 
Table 1: This table represents the Name of the drug, Method used, Column used, Mobile phase, Flow rate, Detection 
and Retention time 
Drug name Method Column used Mobile phase 
Flow 
rate 
Detection 
Retention 
time 
Donepezil HCl 
tablets 
RPHPLC 
isocratic 
mode 
C18 column 250mm 
x 4.6mm(l x d) 
methanol : phosphate 
buffer : Triethylamine 
(60:40:0.5) % v/v 
1ml/min   
Donepezil 
hydrochloride 
RPHPLC 
isocratic 
mode 
phenyl RP 250 × 4.6 
mm i.d 
methanol, 0.02M phosphate 
Buffer (pH 7.5 ± 0.1) and 
triethylamine in the ratio 
60: 40: 0.5 v/v 
1 ml/min UV 268 nm 7.05 min 
Donepezil  HCl  
tablets 
RPHPLC 
isocratic 
mode 
Xterra  RP  C 18,  
250  x  4.6  mm 
Potassium dihydrogen  
orthophosphate  Buffer  
and  Acetonitrile  (80:20)% 
v/v 
1 ml/min 230 nm  
Donepezil   RPHPLC 
isocratic 
mode 
C18 (4.6 X 250 mm 
3.5μm). 
Methanol: buffer 
(60:40%v/v) 
1 ml/min   
Donepezil RPHPLC 
isocratic 
mode 
Inertsil C8-3, 25 cm 
x 4.6-mm, 5 μ 
buffer: methanol: 
triethylamine (550:450:5) 
v/v 
1ml/min 271 nm  
Donepezil 
hydrochloride 
RPHPLC 
isocratic 
mode 
C18 reversed phase 
column 
acetate buffer-Acetonitrile 
(50:50v/v) 
1 ml/min 230nm  
Galantamine 
Hydrobromide 
RPHPLC 
isocratic 
mode 
C18 column 1 mM ammonium formate: 
acetonitrile (30:70) 
0.4 
ml/min 
UV detector 
289 nm 
 
Galantamine HBr RPHPLC 
isocratic 
mode 
C18 analytical 
reverse phase column 
solution A and solution B 
(75:25v/v) 
1ml/min PDA detector 
230 nm 
 
Galantamine 
hydrobromide 
RP-HPLC reverse phase Inertsil 
ODS 
phosphate buffer pH 6.3: 
acetonitrile as the mobile 
phase in the ratio of 60:40, 
v/v 
1 ml/min 285 nm 4.1 min 
Memantine HCl 
and Donepezil HCl 
RP-HPLC Hypersil BDS (4.6 x 
150 mm, 5μ) 
Sodium dihydrogen ortho 
phosphate: Acetonitrile 
(30:70v/v) 
1 ml/min UV Detector 2.833 min. 
and 4.777 
min 
Memantine HCl 
and Donepezil HCl 
RP-HPLC Amino, Column 250 
X 4.8 Mm (5 µm) 
HPLC Grade Water 
(100%) 
1 ml/min Refractive 
Index 
Detector 
3.561 min. 
and 4.212 
min 
Memantine  RP-HPLC Inertsil ODS-3V, 250 
x 4.6, 5μm 
0.02 M ammonium acetate 
buffer and methanol in the 
ratio (12:88) 
1.5 
ml/min 
UV detection 
226 nm 
8.62 
Rivastigmine  RP-HPLC Thermo Hypersil C4 
column (25 cm X 4.6 
mm, 5 μm) 
0.01 M ammonium acetate 
buffer adjusted to pH 4.0 
with orthophosphoric acid 
and Acetonitrile (60:40, 
v/v) 
1 ml/min UV detection 
220 nm 
4.75 
Rivastigmine bulk 
dosages form 
RP-HPLC C-18 Potassium dihydrogen 
phosphate buffer and 
acetonitrile (70/30 v/v) 
1 ml/min UV detector 
217nm 
3.66±25min 
Rivastigmine 
tartrate 
RP-HPLC C-18 RP-HPLC 
column 
0.01M ammonium acetate 
buffer and acetonitrile 
(70:30 v/v) 
1 ml/min UV detector 
219nm 
4.40min 
Tacrine 
hydrochloride 
RP-HPLC C18 column 0.05M triethylamine: 
acetonitrile (80: 20,); 
1.5 ml/ 
minutes 
UV detector 
243nm 
5.8 minutes 
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5. Conclusion 
Herein, an effort was made to review recent trends 
in AD. Well designed, independent cost effective analyses 
of Alzheimer’s drugs are lacking. Evidence from literature 
review suggests that there may be cost effective treatment 
for AD. The new method development and validation for 
AD and the role of drugs, that are assumed to contribute in 
the significant fields for advanced research is lacking. 
There is significant active investigation ongoing in the 
analytical method development and validation as targets for 
treatment of AD. Thus, it is hoped that all these lines of 
ongoing research, combined, should lead to a deeper 
understanding. Thus, we conclude that these categories of 
drugs discussed in this review can be potentially targeted 
for research and development for the treatment of AD. 
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